Description
Market Report Coverage – Precision Psychiatry
Market Segmentation
• Product Type– Products and Services
• Sample Type – Blood-Based and Non-Blood-Based (Saliva, CSF, Urine, and others)
• Biomarker Type – Genetic Biomarker and Protein Biomarker
• Technology – Sequencing (NGS and Sanger Sequencing), Polymerase Chain Reaction (RT-PCR and dPCR), Microarray, Immunoassay, Liquid Chromatography-Mass Spectrometry (LC-MS) and Other Technologies
• Application – Alzheimer’s Disease, Parkinson’s Disease, Autism, Depression, Bipolar Disease, and Other Applications
• End User – Academic and Research Institutions, Hospitals and Diagnostic Laboratories, and Other End Users
Regional Segmentation
• North America – U.S., and Canada
• Europe – Germany, U.K., France, Italy, Spain, Netherlands, and Rest-of-Europe
• Asia-Pacific – China, Japan, India, Australia, South Korea, and Rest-of-Asia-Pacific
• Latin America – Brazil, Mexico, and Rest-of-Latin America
• Rest-of-the-World
Growth Drivers
• Decreasing Cost of Sequencing
• Increasing Adoption of Inorganic Growth Strategies
• Global Increase in Mental Health Burden
Market Challenges
• Lack of Established Regulatory Policies for Precision Diagnostics in the Field of Precision Psychiatry
• Lack of Awareness for Precision Psychiatry Diagnostics
Market Opportunities
• Increased Use of Precision Diagnostics for Drug Development by Pharmaceutical and Companion Diagnostics Companies
• Massive Scope for Adoption of NGS-Based Genetic Tests in Emerging Markets
Key Companies Profiled
Illumina, Inc., F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., QIAGEN N.V., Quest Diagnostics Incorporated, ARUP Laboratories, Invitae Corporation, OPKO Health, Inc., Laboratory Corporation of America Holdings, Centogene N.V., Thermo Fisher Scientific Inc., Myriad Genetics, Inc., Konica Minolta, Inc., Fulgent Genetics, PreventionGenetics
Key Questions Answered in this Report:
• How is precision psychiatry revolutionizing the field of mental health diagnostics?
• What are the major market drivers, challenges, and opportunities in the global precision psychiatry market?
• What are the underlying structures resulting in the emerging trends within the global precision psychiatry market?
• How is the COVID-19 pandemic impacting the global precision psychiatry landscape?
• What are the key development strategies that are being implemented by the major players in order to sustain in the competitive market?
• What are the key regulatory implications in developed and developing regions pertaining to precision psychiatry?
• What are the potential entry barriers, which are expected to be faced by the companies willing to enter a particular region?
• How is each segment of the market expected to grow during the forecast period from 2021 to 2026, and what is the anticipated revenue to be generated by each of the segments? Following are the segments:
o Product Type (Products and Services)
o Sample (Blood-Based and Non-Blood-Based)
o Biomarker (Genetic Biomarkers and Protein)
o Technology (Sequencing, PCR, Microarray, Immunoassay, LC/MS, and Others)
o Application (Parkinson’s Disease, Autism, Alzheimer’s Disease, Depression, Schizophrenia, Bipolar Disorder, and Others)
o End User (Hospitals and Diagnostic Laboratories, Academic and Research Institutions, and Others)
o Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)
• What are the growth opportunities for the companies in the region of their operation?
• Who are the leading players with significant offerings in the global precision psychiatry market?
• Which companies are anticipated to be highly disruptive in the future, and why?
• What are the current unmet needs that are being faced in the global precision psychiatry market?
Market Overview
Our healthcare experts have found the precision psychiatry market to be one of the most rapidly evolving and dynamic markets, and the global market for precision psychiatry is predicted to grow at a CAGR of 17.26% over the forecast period of 2021-2026. The market is driven by certain factors, which include decreasing cost of sequencing, increasing adoption of inorganic growth strategies, and global increase in mental health burden, that are fuelling the growth of the global precision psychiatry market.
The market is favored by the developments in the field of molecular diagnostics, which are used for the diagnosis and assessment of psychiatric disorders. Currently, the precision psychiatry industry is witnessing an upsurge due to the decreasing cost of sequencing, increasing adoption of inorganic growth strategies, and global increase in mental health burden. Additionally, the high adoption of advanced molecular diagnostic technologies by the researchers to conduct genomic and proteomic analysis related to the onset and manifestation of psychiatric disorders are some of the critical factors that are expected to bolster the market growth.
Furthermore, biotechnology companies are focusing on the development of robust precision psychiatry solutions for a wide range of applications to support clinicians in conducting an in-depth molecular analysis.
Within the research report, the market is segmented on the basis of product type, biomarker, sample, technology, application, end user, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
Competitive Landscape
The exponential rise in the number of cases associated with psychiatric disorders has created a buzz among the biotechnology companies to further invest in the development of molecular diagnostics for the assessment of mental disorders, further aiding clinicians to offer precision medicine. Due to the presence of a diverse product portfolio and intense market penetration, Quest Diagnostics Incorporated has been a pioneer in the precision psychiatry ecosystem.
On the basis of region, North America holds the largest share of the precision psychiatry market due to high infusion of funding from the government organizations for conducting research on psychiatric disorders, growing prevalence of mental disorders, growing awareness about precision medicine, and increasing awareness about early detection, among others. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR of 20.54% during the forecast period, 2021-2026.
Table of Contents
Executive Summary
1 Product Definition
1.1 Inclusion and Exclusion
2 Market Scope
2.1 Scope of the Study
2.2 Key Questions Answered in the Report
3 Research Methodology
3.1 Global Precision Psychiatry Market: Research Methodology
3.2 Data Sources
3.2.1 Primary Data Sources
3.2.2 Secondary Data Sources
3.3 Market Estimation Model
3.4 Criteria for Company Profiling
4 Market Overview
4.1 Market Definition
4.2 Market Footprint and Growth Potential
4.3 Future Potential
4.4 COVID-19 Impact: Global Precision Psychiatry Market
5 Market Dynamics
5.1 Overview
5.2 Market Drivers
5.2.1 Decreasing Cost of Sequencing
5.2.2 Increasing Adoption of Inorganic Growth Strategies in the Market
5.2.3 Global Increase in Mental Health Burden
5.3 Market Restraints
5.3.1 Lack of Established Regulatory Policies for Precision Diagnostics in the Field of Precision Psychiatry
5.3.2 Lack of Awareness for Precision Psychiatry Diagnostics
5.4 Market Opportunities
5.4.1 Increased Use of Precision Diagnostics for Drug Development by Pharmaceutical and Companion Diagnostics Companies
5.4.2 Massive Scope for Adoption of NGS-based Genetic Tests in Emerging Markets
6 Industry Insights
6.1 Overview
6.2 Legal Requirements and Framework in the U.S.
6.2.1 FDA Regulation
6.2.2 CMS Regulation
6.3 Legal Requirements and Framework in Europe
6.4 Legal Requirements and Framework in Asia-Pacific
6.4.1 China
6.4.2 Japan
6.4.3 South Korea
6.4.4 Australia
7 Competitive Landscape
7.1 Product Launches
7.2 Product Approvals and Designations
7.3 Synergistic Activities
7.4 Acquisitions
7.5 Funding
7.6 Market Share Analysis, by Company, 2019–2020
7.7 Growth Share Analysis
7.7.1 Growth Share Analysis (by Company)
8 Global Precision Psychiatry Market (by Product Type)
8.1 Overview
8.2 Products
8.3 Services
9 Global Precision Psychiatry Market (by Biomarker Type)
9.1 Overview
9.2 Genetic Biomarkers
9.2.1 Genetic Biomarkers (by Application)
9.2.1.1 Parkinson’s Disease
9.2.1.2 Autism
9.2.1.3 Alzheimer’s Disease
9.2.1.4 Depression
9.2.1.5 Schizophrenia
9.2.1.6 Bipolar Disorder
9.2.1.7 Other Applications
9.3 Protein Biomarkers
9.3.1 Protein Biomarkers (by Application)
9.3.1.1 Parkinson’s Disease
9.3.1.2 Autism
9.3.1.3 Alzheimer’s Disease
9.3.1.4 Depression
9.3.1.5 Schizophrenia
9.3.1.6 Bipolar Disorder
9.3.1.7 Other Applications
10 Global Precision Psychiatry Market (by Sample)
10.1 Overview
10.2 Blood-Based
10.3 Non-Blood-Based
10.3.1 Saliva
10.3.2 Urine
10.3.3 Cerebral Spinal Fluid (CSF)
10.3.4 Others
11 Global Precision Psychiatry Market (by Technology)
11.1 Overview
11.2 Sequencing
11.2.1 Next-Generation Sequencing (NGS)
11.2.2 Sanger Sequencing
11.3 Polymerase Chain Reaction (PCR)
11.3.1 Real-Time Polymerase Chain Reaction (RT-PCR)
11.3.2 Digital Polymerase Chain Reaction (dPCR)
11.4 Microarray
11.5 Immunoassay
11.6 Liquid Chromatography-Mass Spectrometry (LC-MS)
11.7 Other Technologies
12 Global Precision Psychiatry Market (by Application)
12.1 Overview
12.2 Alzheimer’s Disease
12.2.1 Global Precision Psychiatry Market for Alzheimer’s Disease (by Technology)
12.3 Parkinson’s Disease
12.3.1 Global Precision Psychiatry Market for Parkinson’s Disease (by Technology)
12.4 Autism
12.4.1 Global Precision Psychiatry Market for Autism (by Technology)
12.5 Depression
12.5.1 Global Precision Psychiatry Market for Depression (by Technology)
12.6 Schizophrenia
12.6.1 Global Precision Psychiatry Market for Schizophrenia (by Technology)
12.7 Bipolar Disorder
12.7.1 Global Precision Psychiatry Market for Bipolar Disorder (by Technology)
12.8 Other Applications
13 Global Precision Psychiatry Market (by End User)
13.1 Overview
13.2 Hospitals and Diagnostic Laboratories
13.3 Academic and Research Institutions
13.4 Other End Users
14 Global Precision Psychiatry Market (by Region)
14.1 Overview
14.2 North America
14.2.1 U.S.
14.2.2 Canada
14.3 Europe
14.3.1 Germany
14.3.2 UK.
14.3.3 France
14.3.4 Italy
14.3.5 Spain
14.3.6 Netherlands
14.3.7 Rest-of-Europe
14.4 Asia-Pacific
14.4.1 China
14.4.2 Japan
14.4.3 South Korea
14.4.4 Australia
14.4.5 India
14.4.6 Rest-of-Asia-Pacific
14.5 Latin America
14.5.1 Brazil
14.5.2 Mexico
14.5.3 Rest-of-Latin America
14.6 Rest-of-the-World (RoW)
15 Company Profiles
15.1 Overview
15.2 Illumina, Inc.
15.2.1 Company Overview
15.2.2 Role of Illumina, Inc. in the Global Precision Psychiatry Market
15.2.3 Financials
15.2.4 Key Insights About Financial Health of the Company
15.2.5 SWOT Analysis
15.3 F. Hoffmann-La Roche Ltd.
15.3.1 Company Overview
15.3.2 Role of F. Hoffmann-La Roche Ltd in the Global Precision Psychiatry Market
15.3.3 Financials
15.3.4 Key Insights About Financial Health of the Company
15.3.5 SWOT Analysis
15.4 Bio-Rad Laboratories, Inc.
15.4.1 Company Overview
15.4.2 Role of Bio-Rad Laboratories, Inc. in the Global Precision Psychiatry Market
15.4.3 Financials
15.4.4 Key Insights About Financial Health of the Company
15.4.5 SWOT Analysis
15.5 QIAGEN N.V.
15.5.1 Company Overview
15.5.2 Role of QIAGEN N.V. in the Global Precision Psychiatry Market
15.5.3 Financials
15.5.4 Key Insights about Financial Health of the Company
15.5.5 SWOT Analysis
15.6 Quest Diagnostics Incorporated
15.6.1 Company Overview
15.6.2 Role of Quest Diagnostics Incorporated in the Global Precision Psychiatry Market
15.6.3 Financials
15.6.4 SWOT Analysis
15.7 ARUP Laboratories
15.7.1 Company Overview
15.7.2 Role of ARUP Laboratories in the Global Precision Psychiatry Market
15.7.3 SWOT Analysis
15.8 Invitae Corporation
15.8.1 Company Overview
15.8.2 Role of Invitae Corporation, Inc. in the Global Precision Psychiatry Market
15.8.3 Financials
15.8.4 Key Insights About Financial Health of the Company
15.8.5 SWOT Analysis
15.9 OPKO Health, Inc.
15.9.1 Company Overview
15.9.2 Role of OPKO Health, Inc. in the Global Precision Psychiatry Market
15.9.3 Financials
15.9.4 Key Insights About Financial Health of the Company
15.9.5 SWOT Analysis
15.1 Laboratory Corporation of America Holdings
15.10.1 Company Overview
15.10.2 Role of Laboratory Corporation of America Holdings in the Global Precision Psychiatry Market
15.10.3 Financials
15.10.4 SWOT Analysis
15.11 CENTOGENE N.V.
15.11.1 Company Overview
15.11.2 Role of CENTOGENE N.V. in Precision Psychiatry Market
15.11.3 Financials
15.11.4 Key Insights About Financial Health of the Company
15.11.5 SWOT Analysis
15.12 Thermo Fisher Scientific Inc.
15.12.1 Company Overview
15.12.2 Role of Thermo Fisher Scientific Inc. in Global Precision Psychiatry Market
15.12.3 Financials
15.12.4 Key Insights About Financial Health of the Company
15.12.5 SWOT Analysis
15.13 Myriad Genetics, Inc.
15.13.1 Company Overview
15.13.2 Role of Myriad Genetics, Inc. in the Global Precision Psychiatry Market
15.13.3 Financials
15.13.4 Key Insights About Financial Health of the Company
15.13.5 SWOT Analysis
15.14 Konica Minolta, Inc.
15.14.1 Company Overview
15.14.2 Role of Konica Minolta, Inc. in the Global Precision Psychiatry Market
15.14.3 Financials
15.14.4 Key Insights About Financial Health of the Company
15.14.5 SWOT Analysis
15.15 Fulgent Genetics
15.15.1 Company Overview
15.15.2 Role of Fulgent Genetics in the Global Precision Psychiatry Market
15.15.3 Financials
15.15.4 Key Insights About Financial Health of the Company
15.15.5 SWOT Analysis
15.16 PreventionGenetics
15.16.1 Company Overview
15.16.2 Role of the PreventionGenetics in the Global Precision Psychiatry Market
15.16.3 SWOT Analysis
List of Tables
Table 8.1: Products Offered by Key Players
Table 8.2: Services Offered by Key Players
Table 12.1: Precision Psychiatry Products for Alzheimer’s Disease
Table 12.2: Precision Psychiatry Services for Alzheimer’s Disease
Table 12.3: Precision Psychiatry Products for Parkinson’s Disease
Table 12.4: Precision Psychiatry Services for Parkinson’s Disease
Table 12.5: Precision Psychiatry Products for Autism
Table 12.6: Precision Psychiatry Services for Autism
Table 12.7: Precision Psychiatry Products for Depression
Table 12.8: Precision Psychiatry Service for Depression
Table 12.9: Precision Psychiatry Products for Schizophrenia
Table 12.10: Precision Psychiatry Services for Schizophrenia
Table 12.11: Precision Psychiatry Products for Bipolar Disorder
Table 12.12: Precision Psychiatry Service for Bipolar Disorder
Table 12.13: Precision Psychiatry Products for Other Applications
Table 12.14: Precision Psychiatry Service for Other Applications
List of Figures
Figure 1: Global Burden of Prominent Psychiatric Disorders (2014-2019)
Figure 2: Impact Analysis of Market Drivers and Market Challenges on Global Precision Psychiatry Market
Figure 3: Global Precision Psychiatry Market (by Product Type), $Million, 2020 Vs. 2026
Figure 4: Global Precision Psychiatry Market (by Biomarker), $Million, 2020 Vs. 2026
Figure 5: Global Precision Psychiatry Market (by Sample), $Million, 2020 Vs. 2026
Figure 6: Global Precision Psychiatry Market (by Technology), $Million, 2020 Vs. 2026
Figure 7: Global Precision Psychiatry Market (by Application), $Million, 2020 Vs. 2026
Figure 8: Global Precision Psychiatry Market (by End User), $Million, 2020 Vs. 2026
Figure 9: Global Precision Psychiatry: Market Snapshot
Figure 2.1: Global Precision Psychiatry Market: Segmentation
Figure 3.1: Global Precision Psychiatry Market: Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: Global Precision Psychiatry Market, $Million, 2020-2026
Figure 4.2: Global Precision Psychiatry Market: COVID-19 Impact
Figure 5.1: Decreasing Cost and Increasing Output (TB) of Genome Sequencing (2009-2025)
Figure 5.2: Synergistic Activities, FY2017-FY2020
Figure 5.3: Global Burden of Prominent Psychiatric Disorders (2014-2019)
Figure 6.1: FDA IVD Classification and Regulatory Process
Figure 6.2: Key Changes in EU IVD Regulation 2017/746
Figure 6.3: Europe’s IVD Regulatory Approval Process
Figure 6.4: Medical Device Regulatory Approval Process in China
Figure 6.5: Medical Device Regulatory Approval Process in South Korea
Figure 6.6: Classification of IVD Devices
Figure 6.7: Medical Device (IVDs) Regulatory Approval Process in Australia
Figure 7.1: Share of Key Developments and Strategies, January 2017–March 2021
Figure 7.2: Share of Product Launched (by Company), January 2017–March 2021
Figure 7.3: Share of Product Approvals and Designations (by Company), January 2017-March 2021
Figure 7.4: Share of Synergistic Activities (by Company), January 2017-March 2021
Figure 7.5: Share of Acquisitions (by Company), January 2017-March 2021
Figure 7.6: Share of Funding (by Company), January 2017-March 2021
Figure 7.7: Market Share Analysis for Global Precision Psychiatry Market, 2019 and 2020
Figure 7.8: Growth Share Analysis for Global Precision Psychiatry Market (by Company), 2020
Figure 8.1: Global Precision Psychiatry Market (by Product Type)
Figure 8.2: Global Precision Psychiatry Market (by Product Type), 2020-2026
Figure 8.3: Global Precision Psychiatry Market (Product), $Million, 2020-2026
Figure 8.4: Global Precision Psychiatry Market (Services), $Million, 2020-2026
Figure 9.1: Global Precision Psychiatry Market (by Biomarker Type), $Million, 2020-2026
Figure 9.2: Global Precision Psychiatry Market (by Biomarker Type), 2020 and 2026
Figure 9.3: Global Precision Psychiatry Market (Genetic Biomarkers), $Million, 2020-2026
Figure 9.4: Global Precision Psychiatry Market for Genetic Biomarkers (Parkinson’s Disease), $Million, 2020-2026
Figure 9.5: Global Precision Psychiatry Market for Genetic Biomarkers (Autism), $Million, 2020-2026
Figure 9.6: Global Precision Psychiatry Market for Genetic Biomarkers (Alzheimer’s Disease), $Million, 2020-2026
Figure 9.7: Global Precision Psychiatry Market for Genetic Biomarkers (Depression), $Million, 2020-2026
Figure 9.8: Global Precision Psychiatry Market for Genetic Biomarkers (Schizophrenia), $Million, 2020-2026
Figure 9.9: Global Precision Psychiatry Market for Genetic Biomarkers (Bipolar Disorder), $Million, 2020-2026
Figure 9.10: Global Precision Psychiatry Market for Genetic Biomarkers (Other Applications), $Million, 2020-2026
Figure 9.11: Global Precision Psychiatry Market (Protein Biomarkers), $Million, 2020-2026
Figure 9.12: Global Precision Psychiatry Market for Protein Biomarkers (Parkinson’s Disease), $Million, 2020-2026
Figure 9.13: Global Precision Psychiatry Market for Protein Biomarkers (Autism), $Million, 2020-2026
Figure 9.14: Global Precision Psychiatry Market for Protein Biomarkers (Alzheimer’s Disease), $Million, 2020-2026
Figure 9.15: Global Precision Psychiatry Market for Protein Biomarkers (Depression), $Million, 2020-2026
Figure 9.16: Global Precision Psychiatry Market for Protein Biomarkers (Schizophrenia), $Million, 2020-2026
Figure 9.17: Global Precision Psychiatry Market for Protein Biomarkers (Bipolar Disorder), $Million, 2020-2026
Figure 9.18: Global Precision Psychiatry Market for Protein Biomarkers (Other Applications), $Million, 2020-2026
Figure 10.1: Global Precision Psychiatry Market (by Sample)
Figure 10.2: Global Precision Psychiatry Market (by Sample), 2020-2026
Figure 10.3: Global Precision Psychiatry Market (Blood-Based), $Million, 2020-2026
Figure 10.4: Global Precision Psychiatry Market (Non-Blood-Based), $Million, 2020-2026
Figure 10.5: Global Precision Psychiatry Market (by Non-Blood-based Samples), $Million, 2020-2026
Figure 10.6: Global Precision Psychiatry Market (Saliva), $Million, 2020-2026
Figure 10.7: Global Precision Psychiatry Market (Urine), $Million, 2020-2026
Figure 10.8: Global Precision Psychiatry Market (CSF), $Million, 2020-2026
Figure 10.9: Global Precision Psychiatry Market (Other Samples), $Million, 2020-2026
Figure 11.1: Global Precision Psychiatry Market (by Technology)
Figure 11.2: Global Precision Psychiatry Market (by Technology), 2020-2026
Figure 11.3: Global Precision Psychiatry Market (by Sequencing), $Million, 2020-2026
Figure 11.4: Global Precision Medicine Market (by Sequencing), 2020 and 2026
Figure 11.5: Global Precision Psychiatry Market (by NGS), $Million, 2020-2026
Figure 11.6: Global Precision Psychiatry Market (by Sanger Sequencing), $Million, 2020-2026
Figure 11.7: Global Precision Psychiatry Market (by PCR), $Million, 2020-2026
Figure 11.8: Global Precision Psychiatry Market (by PCR), 2020 and 2026
Figure 11.9: Global Precision Psychiatry Market (RT-PCR), $Million, 2020-2026
Figure 11.10: Global Precision Psychiatry Market (dPCR), $Million, 2020-2026
Figure 11.11: Global Precision Psychiatry Market (Microarray), $Million, 2020-2026
Figure 11.12: Global Precision Psychiatry Market (Immunoassay), $Million, 2020-2026
Figure 11.13: Global Precision Psychiatry Market (LC-MS), $Million, 2020-2026
Figure 11.14: Global Precision Psychiatry Market (Others Technologies), $Million, 2020-2026
Figure 12.1: Global Precision Psychiatry Market (by Application)
Figure 12.2: Global Precision Psychiatry Market (by Application), $Million, 2020-2026
Figure 12.3: Global Precision Psychiatry Market (Alzheimer’s Disease), $Million, 2020-2026
Figure 12.4: Growth-Share Analysis for Global Precision Psychiatry Market for Alzheimer’s Disease (by Technology), 2020-2026
Figure 12.5: Global Precision Psychiatry Market (Parkinson’s Disease), $Million, 2020-2026
Figure 12.6: Growth-Share Analysis for Global Precision Psychiatry Market for Parkinson’s Disease (by Technology), 2020-2026
Figure 12.7: Global Precision Psychiatry Market (Autism), $Million, 2020-2026
Figure 12.8: Growth-Share Analysis for Global Precision Psychiatry Market for Autism (by Technology), 2020-2026
Figure 12.9: Global Precision Psychiatry Market (Depression), $Million, 2020-2026
Figure 12.10: Growth-Share Analysis for Global Precision Psychiatry Market for Depression (by Technology), 2020-2026
Figure 12.11: Global Precision Psychiatry Market (Schizophrenia), $Million, 2020-2026
Figure 12.12: Growth-Share Analysis for Global Precision Psychiatry Market for Schizophrenia (by Technology), 2020-2026
Figure 12.13: Global Precision Psychiatry Market (Bipolar Disorder), $Million, 2020-2026
Figure 12.14: Growth-Share Analysis for Global Precision Psychiatry Market for Bipolar Disorder (by Technology), 2020-2026
Figure 12.15: Global Precision Psychiatry Market (Other Applications), $Million, 2020-2026
Figure 13.1: Global Precision Psychiatry Market (by End User)
Figure 13.2: Global Precision Psychiatry Market (by End User), $Million, 2020-2026
Figure 13.3: Global Precision Psychiatry Market (Hospitals and Diagnostic Laboratories), $Million, 2020-2026
Figure 13.4: Global Precision Psychiatry Market (Academic and Research Institutions), $Million, 2020-2026
Figure 13.5: Global Precision Psychiatry Market (Other End Users), $Million, 2020-2026
Figure 14.1: Global Precision Psychiatry Market (by Region), 2020 and 2026
Figure 14.2: Global Precision Psychiatry Market (by Region), $Million, 2020-2026
Figure 14.3: Global Precision Psychiatry Market (by Region), 2020-2026
Figure 14.4: North America Precision Psychiatry Market, $Million, 2020-2026
Figure 14.5: North America: Market Dynamics
Figure 14.6: North America Precision Psychiatry Market (by Country), $Million, 2020-2026
Figure 14.7: U.S. Precision Psychiatry Market, $Million, 2020-2026
Figure 14.8: Canada Precision Psychiatry Market, $Million, 2020-2026
Figure 14.9: Europe Precision Psychiatry Market, $Million, 2020-2026
Figure 14.10: Europe: Market Dynamics
Figure 14.11: Europe Precision Psychiatry Market (by Country), $Million, 2020-2026
Figure 14.12: Germany Precision Psychiatry Market, $Million, 2020-2026
Figure 14.13: U.K. Precision Psychiatry Market, $Million, 2020-2026
Figure 14.14: France Precision Psychiatry Market, $Million, 2020-2026
Figure 14.15: Italy Precision Psychiatry Market, $Million, 2020-2026
Figure 14.16: Spain Precision Psychiatry Market, $Million, 2020-2026
Figure 14.17: Netherlands Precision Psychiatry Market, $Million, 2020-2026
Figure 14.18: Rest-of-Europe Market, $Million, 2020-2026
Figure 14.19: Asia-Pacific Precision Psychiatry Market, $Million, 2020-2026
Figure 14.20: APAC: Market Dynamics
Figure 14.21: APAC Precision Psychiatry Market (by Country), $Million, 2020-2026
Figure 14.22: China Precision Psychiatry Market, $Million, 2020-2026
Figure 14.23: Japan Precision Psychiatry Market, $Million, 2020-2026
Figure 14.24: South Korea Precision Psychiatry Market, $Million, 2020-2026
Figure 14.25: Australia Precision Psychiatry Market, $Million, 2020-2026
Figure 14.26: India Precision Psychiatry Market, $Million, 2020-2026
Figure 14.27: RoAPAC Precision Psychiatry Market, $Million, 2020-2026
Figure 14.28: Latin America Precision Psychiatry Market, $Million, 2020-2026
Figure 14.29: Latin America: Market Dynamics
Figure 14.30: Latin America Precision Psychiatry Market (by Country), $Million, 2020-2026
Figure 14.31: Brazil Precision Psychiatry Market, $Million, 2020-2026
Figure 14.32: Mexico Precision Psychiatry Market, $Million, 2020-2026
Figure 14.33: Rest-of-Latin America Precision psychiatry Market, $Million, 2020-2026
Figure 14.34: RoW Precision Psychiatry Market, $Million, 2021-2026
Figure 15.1: Total Number of Companies Profiled
Figure 15.2: Illumina, Inc.: Product Portfolio
Figure 15.3: Illumina, Inc.: Overall Financials, 2018-2020
Figure 15.4: Illumina, Inc.: Revenue (by Segment), 2018-2020
Figure 15.5: Illumina, Inc.: Revenue (by Region), 2018-2020
Figure 15.6: Illumina, Inc.: R&D Expenditure, 2018-2020
Figure 15.7: Illumina, Inc.: SWOT Analysis
Figure 15.8: F. Hoffmann-La Roche Ltd: Portfolio
Figure 15.9: F. Hoffmann-La Roche Ltd: Overall Financials, 2018-2020
Figure 15.10: F. Hoffmann-La Roche Ltd: Sales (by Segment), 2018-2020
Figure 15.11: F. Hoffmann-La Roche Ltd: Sales (by Region), 2018-2020
Figure 15.12: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2018-2020
Figure 15.13: F. Hoffmann-La Roche: SWOT Analysis
Figure 15.14: Bio-Rad Laboratories, Inc.: Portfolio
Figure 15.15: Bio-Rad Laboratories, Inc.: Overall Financials, 2018-2020
Figure 15.16: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2018-2020
Figure 15.17: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2018-2020
Figure 15.18: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2018-2020
Figure 15.19: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 15.20: QIAGEN N.V.: Portfolio
Figure 15.21: QIAGEN N.V.: Overall Financials, 2018-2020
Figure 15.22: QIAGEN N.V.: Revenue (by Segment), 2018-2020
Figure 15.23: QIAGEN N.V.: Revenue (by Region), 2018-2020
Figure 15.24: QIAGEN N.V.: R&D Expenditure, 2018-2020
Figure 15.25: QIAGEN N.V.: SWOT Analysis
Figure 15.26: Quest Diagnostics Incorporated: Portfolio
Figure 15.27: Quest Diagnostics Incorporated: Overall Financials, 2018-2020
Figure 15.28: Quest Diagnostics Incorporated: Revenue (by Business Segment), 2018-2020
Figure 15.29: Quest Diagnostics Incorporated: SWOT Analysis
Figure 15.30: ARUP Laboratories: Portfolio
Figure 15.31: ARUP Laboratories: SWOT Analysis
Figure 15.32: Invitae Corporation: Portfolio
Figure 15.33: Invitae Corporation: Overall Financials, 2018-2020
Figure 15.34: Invitae Corporation: Revenue (by Segment), 2018-2020
Figure 15.35: Invitae Corporation: Revenue (by Geography), 2018-2020
Figure 15.36: Invitae Corporation: R&D Expenditure, 2018-2020
Figure 15.37: Invitae Corporation: SWOT Analysis
Figure 15.38: OPKO Health, Inc.: Portfolio
Figure 15.39: OPKO Health, Inc.: Overall Financials, 2018-2020
Figure 15.40: OPKO Health, Inc.: Revenue (by Segment), 2018-2020
Figure 15.41: OPKO Health, Inc.: Revenue (by Region), 2018-2020
Figure 15.42: OPKO Health, Inc.: R&D Expenditure, 2018-2020
Figure 15.43: OPKO Health, Inc.: SWOT Analysis
Figure 15.44: Laboratory Corporation of America Holdings: Portfolio
Figure 15.45: Laboratory Corporation of America Holdings: Overall Financials, 2018-2020
Figure 15.46: Laboratory Corporation of America Holdings: Revenue (by Segment), 2018-2020
Figure 15.47: Laboratory Corporation of America Holdings: Revenue (by Region), 2019
Figure 15.48: Laboratory Corporation of America Holdings: SWOT Analysis
Figure 15.49: CENTOGENE N.V.: Overall Product Portfolio
Figure 15.50: CENTOGENE N.V.: Overall Financials, 2017-2019
Figure 15.51: CENTOGENE N.V.: Revenue (by Segment), 2017-2019
Figure 15.52: CENTOGENE N.V.: Sales (by Region), 2017-2019
Figure 15.53: CENTOGENE N.V.: R&D Expenditure, 2017-2019
Figure 15.54: CENTOGENE N.V.: SWOT Analysis
Figure 15.55: Thermo Fisher Scientific, Inc.: Product Portfolio
Figure 15.56: Thermo Fisher Scientific Inc.: Overall Financials, 2018-2020
Figure 15.57: Thermo Fisher Scientific Inc.: Revenue (by Business Segment), 2018-2020
Figure 15.58: Thermo Fisher Scientific Inc.: Revenue (by Region), 2018-2020
Figure 15.59: Thermo Fisher Scientific Inc.: R&D Expenditure, 2018-2020
Figure 15.60: Thermo Fisher Scientific Inc.: SWOT Analysis
Figure 15.61: Myriad Genetics, Inc.: Product Portfolio
Figure 15.62: Myriad Genetics, Inc.: Overall Financials, 2018-2020
Figure 15.63: Myriad Genetics, Inc.: Revenue (by Business Segment), 2018-2020
Figure 15.64: Myriad Genetics, Inc.: R&D Expenditure, 2018-2020
Figure 15.65: Myriad Genetics, Inc.: SWOT Analysis
Figure 15.66: Konica Minolta, Inc: Product portfolio
Figure 15.67: Konica Minolta, Inc.: Overall Financials, 2017-2019
Figure 15.68: Konica Minolta, Inc.: Revenue (by Business Segment), 2017-2019
Figure 15.69: Konica Minolta, Inc.: Regional revenue, 2017-2019
Figure 15.70: Konica Minolta, Inc.: R&D Expenditure, 2017-2019
Figure 15.71: Konica Minolta, Inc: SWOT Analysis
Figure 15.72: Fulgent Genetics: Product Portfolio
Figure 15.73: Fulgent Genetics: Overall Financials, 2018-2020
Figure 15.74: Fulgent Genetics: Revenue (by Business Segment), 2018-2020
Figure 15.75: Fulgent Genetics: Revenue (by Region), 2018-2020
Figure 15.76: Fulgent Genetics: R&D Expenditure, 2018-2020
Figure 15.77: Fulgent Genetics: SWOT Analysis
Figure 15.78: PreventionGenetics: Product portfolio
Figure 15.79: PreventionGenetics: SWOT Analysis
Reviews
There are no reviews yet.